RESUMEN
BACKGROUND: In 1993, Chitayat et al., reported a newborn with hyperphalangism, facial anomalies, and bronchomalacia. We identified three additional families with similar findings. Features include bilateral accessory phalanx resulting in shortened index fingers; hallux valgus; distinctive face; respiratory compromise. OBJECTIVES: To identify the genetic aetiology of Chitayat syndrome and identify a unifying cause for this specific form of hyperphalangism. METHODS: Through ongoing collaboration, we had collected patients with strikingly-similar phenotype. Trio-based exome sequencing was first performed in Patient 2 through Deciphering Developmental Disorders study. Proband-only exome sequencing had previously been independently performed in Patient 4. Following identification of a candidate gene variant in Patient 2, the same variant was subsequently confirmed from exome data in Patient 4. Sanger sequencing was used to validate this variant in Patients 1, 3; confirm paternal inheritance in Patient 5. RESULTS: A recurrent, novel variant NM_006494.2:c.266A>G p.(Tyr89Cys) in ERF was identified in five affected individuals: de novo (patient 1, 2 and 3) and inherited from an affected father (patient 4 and 5). p.Tyr89Cys is an aromatic polar neutral to polar neutral amino acid substitution, at a highly conserved position and lies within the functionally important ETS-domain of the protein. The recurrent ERF c.266A>C p.(Tyr89Cys) variant causes Chitayat syndrome. DISCUSSION: ERF variants have previously been associated with complex craniosynostosis. In contrast, none of the patients with the c.266A>G p.(Tyr89Cys) variant have craniosynostosis. CONCLUSIONS: We report the molecular aetiology of Chitayat syndrome and discuss potential mechanisms for this distinctive phenotype associated with the p.Tyr89Cys substitution in ERF.
Asunto(s)
Anomalías Múltiples/genética , Síndrome de Dandy-Walker/genética , Discapacidades del Desarrollo/genética , Huesos Faciales/anomalías , Proteínas Represoras/genética , Anomalías Múltiples/fisiopatología , Broncomalacia/genética , Broncomalacia/fisiopatología , Síndrome de Dandy-Walker/fisiopatología , Discapacidades del Desarrollo/fisiopatología , Exoma/genética , Cara/fisiopatología , Huesos Faciales/fisiopatología , Femenino , Hallux Valgus/genética , Hallux Valgus/fisiopatología , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Recién Nacido , Masculino , FenotipoRESUMEN
STUDY QUESTION: Does developmental exposure to the combination of hyperandrogenemia and western-style diet (WSD) worsen adult metabolic function compared to either treatment alone? SUMMARY ANSWER: Young female rhesus macaques treated for 3 years, beginning at menarche, with combined testosterone (T) and WSD have increased weight gain and insulin resistance compared to controls and animals treated with either T or WSD alone. WHAT IS KNOWN ALREADY: Hyperandrogenemia is a well-established component of polycystic ovary syndrome (PCOS) and can be observed in peripubertal girls, indicating a potential pubertal onset of the disease. Obesity is often associated with hyperandrogenemia in peripubertal girls, and overweight girls appear to be at higher risk for the development of PCOS later in life. STUDY DESIGN, SIZE, DURATION: Juvenile (2.5- year old) female rhesus macaques were divided into four groups (n = 10/group): control animals receiving cholesterol implants and a control diet with 15% of calories derived from fat (C), animals receiving T implants (mean serum levels: 1.35 ± 0.01 ng/ml) and a control diet (T), animals receiving a cholesterol implant and a WSD with 36% of calories derived from fat (WSD) and animals receiving a T implant and a WSD (T + WSD). Animals were maintained on the treatments for 36 months and were 5.5 years old at study completion. PARTICIPANTS/MATERIALS, SETTING, METHODS: Metabolic testing consisted of body measurements including weight, dual-energy X-ray absorptiometry scans, activity monitoring, and glucose tolerance testing at zero months and at least once every 12 months for the remainder of the study. Indirect calorimetry and serum hormone assays were performed following 36 months of treatment. MAIN RESULTS AND THE ROLE OF CHANCE: Body weight and fat mass gain were significantly increased in T + WSD at 24 and 36 months of treatment compared to the other three groups. Log transformed fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were significantly increased in T + WSD animals at 3 years of treatment compared to all other groups. T-treatment caused a greater rate of decline in activity after 18 months, while food intake and metabolic rate were largely unaffected by treatments. LIMITATIONS REASONS FOR CAUTION: Variability was present in the metabolic parameters measured; however, this is similar to the heterogeneity observed in human populations. WIDER IMPLICATIONS OF THE FINDINGS: Chronic hyperandrogenemia beginning at puberty may exacerbate metabolic dysfunction in women consuming a WSD and account for the increased rates of obesity and insulin resistance observed in PCOS patients. Counseling of female patient populations with elevated androgens about the potential benefit of consuming a lower fat diet could improve long-term metabolic health outcomes. STUDY FUNDING/COMPETING INTEREST(S): Eunice Kennedy Shriver National Institute of Child Health & Human Development P50HD071836 and Oregon National Primate Center Grant P51 OD011092. The authors have no competing conflict of interests to disclose.
Asunto(s)
Adiposidad/fisiología , Peso Corporal/fisiología , Dieta Occidental , Hiperandrogenismo/metabolismo , Resistencia a la Insulina/fisiología , Testosterona/farmacología , Absorciometría de Fotón , Adiposidad/efectos de los fármacos , Animales , Índice de Masa Corporal , Peso Corporal/efectos de los fármacos , Femenino , Prueba de Tolerancia a la Glucosa , Hiperandrogenismo/sangre , Macaca mulatta , Testosterona/sangreRESUMEN
Measurements have been made to determine the solubility of ethane, C2H6, in aqueous solutions of four different surfactants of the linear alkanesulfonate class at 25 degrees C. The surfactants, sodium 1-pentanesulfonate, sodium 1-hexanesulfonate, sodium 1-heptanesulfonate, and sodium 1-octanesulfonate, all share a common head group (-SO-3) and counter ion (Na+), and differ only in the length of the alkyl chain attached to the head group. The solubility of ethane has been determined as a function of surfactant concentration for each surfactant. At surfactant concentrations below the critical micelle concentration (CMC), the solubility of ethane is quite low and differs only slightly from the solubility of ethane in pure water. At concentrations greater than the CMC, the solubility of ethane exhibits a gradual increase with surfactant concentration. At high surfactant concentrations, well in excess of the CMC, the solubility of ethane is found to increase as a linear function of surfactant concentration. From this data it becomes possible to determine the fractional population of the surfactant in the free and micellized states. The solubility data measured for ethane is interpreted in terms of the mass-action model for micelle formation.